Our Takeaways From ACC.26

AI Has Moved From Concept to Clinical Infrastructure

AI was not positioned as a future innovation, but as an active clinical tool integrated across imaging, diagnostics, workflow optimization, and risk stratification. Keynote lectures and late-breaking sessions reinforced AI's role in day-to-day cardiovascular decision-making, not just research experimentation.

Late-Breaking Clinical Trials Continue to Drive Practice Change

Late-breaking clinical trials remained a central pillar of the ACC scientific program, with high-profile presentations spanning thrombosis, structural heart disease, lipid management, pulmonary embolism, and heart failure. Multiple sessions were positioned in prime plenary slots, including joint ACC/New England Journal of Medicine sessions, underscoring the expectation that these data will directly inform clinical decision-making and guideline updates. The breadth of trial designs—from large, global, randomized studies to pragmatic and device-based investigations—reflected a growing emphasis on translating mechanistic and procedural advances into real-world practice.

Cardiovascular Care Is Increasingly Multisystem

A notable thematic shift at ACC.26 was the emphasis on cardiovascular-kidney-metabolic (CKM) integration, with multiple sessions and scientific presentations highlighting the interconnected nature of arrhythmias, diabetes, chronic kidney disease, and heart failure. Rather than treating these conditions as discrete comorbidities, they were consistently framed as components of a shared pathophysiologic continuum, with implications for earlier risk identification, monitoring, and coordinated management. This integrated approach was reinforced by data presented across clinical and real-world evidence sessions that examined cardiovascular risk and rhythm disorders within broader cardiometabolic populations, underscoring the need for cross-disciplinary collaboration and longitudinal care models. Collectively, this framing reflects cardiology's evolving scope—from a traditionally organ-centric specialty to a systems-based discipline that addresses the complex interplay among cardiac, renal, and metabolic disease processes.

Structural Heart Disease and Interventional Cardiology Remain High-Impact

Structural heart disease and interventional cardiology featured prominently throughout the ACC.26 program, with dedicated learning pathways, moderated poster sessions, and technology-focused forums underscoring the continued evolution of device-based therapies. Sessions emphasized not only the expansion of transcatheter treatment options but also the refinement of procedural techniques, patient selection, and peri-procedural management strategies. A strong representation of device science and clinical outcomes research reflected the field's maturation, as newer technologies are increasingly evaluated through rigorous clinical and real-world evidence. There appears to be a shift from proof-of-concept innovation toward optimization and durability, reinforcing the central role of next-generation devices, advanced imaging, and multidisciplinary procedural planning in contemporary structural heart care.

From Guidelines to Practice: Education, Teams, and Engagement Drive Implementation

Across the ACC.26 program, there was a deliberate focus on translating evidence into everyday clinical practice. Multiple sessions were designed to bridge updated clinical guidelines with real-world patient management, explicitly addressing gaps between evidence generation and adoption. Importantly, this emphasis on implementation was reinforced by parallel attention to team-based care models, clinician well-being, and leadership development—positioned alongside scientific content rather than as ancillary topics. The program further supported this shift through increasingly interactive and experiential educational formats, including hands-on learning zones, case-based discussions, and immersive sessions, reflecting a move away from passive, didactic education toward practical skill-building.

Collectively, these elements underscore ACC's evolving educational strategy, recognizing that effective guideline adoption depends not only on data but on engaged care teams, sustainable workforces, and learning environments that mirror real-world clinical complexity.

What's Next?

ACC.26 wasn't just a recap of where cardiovascular care stands today—it was a clear signal of how quickly the field is evolving and how urgent it is to stay engaged with the conversations shaping what's next. The pace of innovation, the push toward real-world application, and the growing complexity of care models all reinforce the importance of staying close to the science and the systems around it. They also underscore the role agency partners play. As communicators, educators, and strategic allies, we don't simply report on the data—we translate it, contextualize it, and help our clients navigate change in meaningful, actionable, and impactful ways. We were proud to be on the ground in New Orleans and energized by the opportunity to help our clients move forward with clarity and confidence. Whether you joined us at ACC.26 or followed along from afar, it's clear that the momentum in cardiology is strong. If you're thinking about how to stay ahead—or how to turn this moment into meaningful growth—we welcome the conversation.